Lai S, Huang Y Q, Liu A Q, Wu H W
Department of Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
J Clin Pharm Ther. 2017 Dec;42(6):783-785. doi: 10.1111/jcpt.12576. Epub 2017 Jun 20.
Wilson's disease (WD) is an inherited disorder in which defective biliary excretion of copper leads to its accumulation. Sodium dimercaptosulphonate (DMPS) is used as the primary therapy in China.
We report two cases, with WD and G6PD deficiency, who developed haemolysis on treatment with DMPS, without any other known risk. After withdrawal of DMPS and administration of dexamethasone and packed red blood cells, the patients recovered.
Clinicians should keep in mind haemolysis as a potentially life-threatening side effect of DMPS in patients with G6PD.
威尔逊病（WD）是一种遗传性疾病，其铜的胆汁排泄存在缺陷，导致铜蓄积。在中国，二巯基丙磺酸钠（DMPS）被用作主要治疗药物。
我们报告了两例患有WD和葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症的患者，他们在接受DMPS治疗时发生了溶血，且无其他已知风险因素。停用DMPS并给予地塞米松和浓缩红细胞后，患者康复。
临床医生应牢记，溶血是DMPS在G6PD缺乏症患者中可能危及生命的副作用。
